Abstract Details

Title Rituximab Treatment of Highly Active Multiple Sclerosis (MS) After Natalizumab-Related Progressive Multifocal Leukoencephalopathy (PML)

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 166

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Cinzia Cordioli, MD (Centro Sclerosi Multipla Spedali Civili di Br) PRESENTER	Dr. Cordioli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Almirall. Dr. Cordioli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Cordioli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Nicola De Rossi	Nicola De Rossi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Nicola De Rossi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for novartis. Nicola De Rossi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen.
	No disclosure on file
Giuseppe Santuccio	No disclosure on file
Ruggero Capra, MD	Dr. Capra has nothing to disclose.